Treatment of monostotic fibrous dysplasia with pamidronate

Kos, Marcin; Łuczak, Klaudiusz; Godziński, Jan; J, Klempous

doi:10.1016/j.jcms.2003.07.009

Cited by 73 publications

(43 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Most experiences have been in patients with polyostotic FD or McCune-Albright Syndrome; there is limited data on patients with craniofacial FD and these experiences were mainly in children. [25] Bisphosphonates are generally safe and well-tolerated, although one reported side-effect is atypical fever. [25] Unfortunately there are no objective methods to assess or predict the outcome of treatment, especially medical treatment.…”

Section: Diagnosis/evaluationmentioning

confidence: 99%

Craniofacial fibrous dysplasia - A review of current management techniques

Guruprasad¹,

Chauhan²

2012

Chron Young Sci

View full text Add to dashboard Cite

Fibrous dysplasia is a pathologic condition of bone of unknown etiology with no apparent familial, hereditary or congenital basis. Lichtenstein first coined the term in 1938 and in 1942 he and Jaffe separated it from other fibro-osseous lesions. It is a bone tumor that, although benign, has the potential to cause significant cosmetic and functional disturbance, particularly in the craniofacial skeleton. Its management poses significant challenges to the surgeon. Craniofacial fibrous dysplasia is 1 of 3 types of fibrous dysplasia that can affect the bones of the craniofacial complex, including the mandible and maxilla. Fibrous dysplasia is a skeletal developmental disorder of the bone-forming mesenchyme that manifests as a defect in osteoblastic differentiation and maturation. It is a lesion of unknown etiology, uncertain pathogenesis, and diverse histopathology. Fibrous dysplasia represents about 2, 5% of all bone tumors and over 7% of all benign tumours. Over the years, we have gained a better understanding of its etiology, clinical behavior, and both surgical and non-surgical treatments.

show abstract

Section: Diagnosis/evaluationmentioning

confidence: 99%

Craniofacial fibrous dysplasia - A review of current management techniques

Guruprasad¹,

Chauhan²

2012

Chron Young Sci

View full text Add to dashboard Cite

show abstract

“…[1][2][3][4] For patients with symptomatic fibrous dysplasia, bisphosphonate therapy is utilized. 5,6 Typical cases of ossifying fibroma and fibrous dysplasia of face and jaw are distinguished by radiological and histological appearances. However, these lesions often present a diagnostic dilemma because of uncertainties concerning the diagnostic significance of specific radiological and histological features; therefore, accurate diagnosis of these lesions can be difficult.…”

mentioning

confidence: 99%

Ossifying fibroma vs fibrous dysplasia of the jaw: molecular and immunological characterization

et al. 2007

View full text Add to dashboard Cite

Ossifying fibroma and fibrous dysplasia of the jaw are maxillofacial fibro-osseous lesions that should be distinguished each other by a pathologist because they show distinct patterns of disease progression. However, both lesions often show similar histological and radiological features, making distinction between the two a diagnostic dilemma. In this study, we performed immunological and molecular analyses of five ossifying fibromas, four cases of extragnathic fibrous dysplasia, and five cases of gnathic fibrous dysplasia with typical histological and radiographic features. First, we examined the difference between fibrous dysplasia and ossifying fibroma in the expression of Runx2 (which determined osteogenic differentiation from mesenchymal stem cells) and other osteogenic markers. Fibroblastic cells in fibrous dysplasia and ossifying fibroma showed strong Runx2 expression in the nucleus. The bone matrices of both lesions showed similar expression patterns for all markers tested except for osteocalcin. Immunoreactivity for osteocalcin was strong throughout calcified regions in fibrous dysplasia, but weak in ossifying fibroma lesions. Second, we performed PCR analysis with peptide nucleic acid (PNA) for mutations at the Arg 201 codon of the alpha subunit of the stimulatory G protein gene (GNAS), which has reported to be a marker for extragnathic fibrous dysplasia. All nine cases of extragnathic or gnathic fibrous dysplasia were positive for this mutation. On the other hand, none of the five cases of ossifying fibroma showed the mutation. These findings indicate that although fibrous dysplasia and ossifying fibroma are similar disease entities, especially in the demonstration of the osteogenic lineage in stromal fibroblast-like cells, they show distinct differences that can be revealed by immunohistochemical detection of osteocalcin expression. Furthermore, PCR analysis with PNA for GNAS mutations at the Arg 201 codon is a useful method to differentiate between fibrous dysplasia and ossifying fibroma.

show abstract

“…Recently, the use of pamidronate, which inhibits the resorptive activity of osteoclasts, appears to be an effective and well-tolerated therapeutic option. 2,6) However, pamidronate treatment does not arrest the expansion of the lesion, so use requires more studies. 1,9) We believe that this new technique is useful, but involves a number of problems.…”

Section: Discussionmentioning

confidence: 99%

Long-Term Outcome of Fibrous Dysplasia: Reconstruction With Dysplastic Bone -Case Report-

Sakamoto

Nakajima

Tamada

et al. 2011

Neurol. Med. Chir.(Tokyo)

View full text Add to dashboard Cite

A 10-year-old girl presented with facial asymmetry associated with bulging of the right fronto-orbital region with no symptoms. Computed tomography demonstrated enlargement of the right zygomatic, frontal, ethmoid, and sphenoid bones. Abnormal proliferation of the bone had obliterated the sphenoid, right frontal sinus, and right ethmoid sinuses. These radiological findings suggested right optic nerve compression due to fibrous dysplasia. Right optic canal decompression was performed. In preparation for recurrence, the resulting bone defect in the right orbital roof was reconstructed using the outer table of the split lesion bone. The removed frontal bone was divided into intact and lesioned parts, and the intact part was returned. The lesioned part was split and the outer table graft used to reconstruct the frontal region. A temporal musculopericranial flap was used to form a barrier between the opened ethmoid sinus and cranial cavity. A protrusion appeared on the left forehead 10 years later, and was shaved to improve the aesthetic appearance. The patient was followed up for a total of 23 years. The use of dysplastic bone involves the risk of recurrence, but the period of recurrence is delayed and the progression stops after adolescence, so the second operation involved only shaving for aesthetic appearance. This procedure is one of the treatments of choice because of easy reconstruction, easy revision, and good results.

show abstract

Treatment of monostotic fibrous dysplasia with pamidronate

Cited by 73 publications

References 13 publications

Craniofacial fibrous dysplasia - A review of current management techniques

Craniofacial fibrous dysplasia - A review of current management techniques

Ossifying fibroma vs fibrous dysplasia of the jaw: molecular and immunological characterization

Long-Term Outcome of Fibrous Dysplasia: Reconstruction With Dysplastic Bone -Case Report-

Contact Info

Product

Resources

About